Edition:
United States

People: Biocon Ltd (BION.BO)

BION.BO on Bombay Stock Exchange

243.40INR
5:59am EDT
Change (% chg)

Rs-2.90 (-1.18%)
Prev Close
Rs246.30
Open
Rs247.00
Day's High
Rs247.00
Day's Low
Rs238.15
Volume
153,633
Avg. Vol
300,774
52-wk High
Rs359.17
52-wk Low
Rs230.00

Chandavarkar, Arun 

Dr. Arun Suresh Chandavarkar, Ph.D., is Chief Executive Officer, Joint Managing Director, Executive Director of Biocon Limited. He is one of India’s bio-pharmaceuticals companies with a therapeutic focus in the areas of diabetes, oncology and cardiovascular disease. Biocon’s subsidiaries, Syngene and Clinigene, are India’s providers of custom research and clinical research services respectively. Dr. Chandavarkar completed his B Tech. in Chemical Engineering from the Indian Institute of Technology, Mumbai in 1984, and was awarded a Ph.D. in BioChemical Engineering from the Massachusetts Institute of Technology, Cambridge, USA in 1990. He joined Biocon as General Manager – Operations in 1990 and subsequently took on the role of President – Operations & Technology. Under his Biocon established at scale in diverse technology platforms spanning microbial fermentation, cell culture, chemical synthesis and purification to address a wide portfolio of products from specialty enzymes to active pharmaceutical ingredients to recombinant therapeutic proteins. His current responsibilities cover all aspects of Biocon’s business with a specific emphasis on strategic management.

Basic Compensation

Total Annual Compensation, INR 25,500,000
Restricted Stock Awards, INR --
Long-Term Incentive Plans, INR --
All Other, INR 1,070,000
Fiscal Year Total, INR 26,570,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --